A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
Latest Information Update: 21 May 2024
At a glance
- Drugs 707 3SBio (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 17 Apr 2024 New trial record